title: Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.
abstract: Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 were used with MF59 adjuvant as a candidate vaccine for a phase 1 safety and immunogenicity trial. Ten of 41 vaccinee serum samples displayed a neutralization titer of > or =1:20 against vesicular stomatitis virus (VSV)-HCV pseudotype, 15 of 36 serum samples tested had a neutralization titer of > or =1:400 against human immunodeficiency virus (HIV)-HCV pseudotype, and 10 of 36 serum samples tested had a neutralization titer of > or =1:20 against cell culture-grown HCV genotype 1a. Neutralizing serum samples had increased affinity levels and displayed >2-fold higher specific activity levels to well-characterized epitopes on E1/E2, especially to the hypervariable region 1 of E2.
authors.affiliation: Department of Internal Medicine and Vaccine and Treatment Evaluation Unit, Saint Louis University, St. Louis, Missouri, USA. rayr@slu.edu
authors.forename: Ranjit
authors.initials: R
authors.lastname: Ray
authors.forename: Keith
authors.initials: K
authors.lastname: Meyer
authors.forename: Arup
authors.initials: A
authors.lastname: Banerjee
authors.forename: Arnab
authors.initials: A
authors.lastname: Basu
authors.forename: Stephen
authors.initials: S
authors.lastname: Coates
authors.forename: Sergio
authors.initials: S
authors.lastname: Abrignani
authors.forename: Michael
authors.initials: M
authors.lastname: Houghton
authors.forename: Sharon E
authors.initials: SE
authors.lastname: Frey
authors.forename: Robert B
authors.initials: RB
authors.lastname: Belshe
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D057134:Antibodies, Neutralizing / Q000097:blood; D005822:Genetic Vectors; D006678:HIV / Q000235:genetics; D016174:Hepacivirus / Q000276:immunology*; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D011136:Polysorbates / Q000008:administration & dosage; D013185:Squalene / Q000008:administration & dosage; D018116:Vesiculovirus / Q000235:genetics; D014759:Viral Envelope Proteins / Q000276:immunology*; D014761:Viral Hepatitis Vaccines / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; C087035:E1 protein, Hepatitis C virus; D018937:Hepatitis C Antibodies; C089950:MF59 oil emulsion; D011136:Polysorbates; D014759:Viral Envelope Proteins; D014761:Viral Hepatitis Vaccines; C091015:glycoprotein E2, Hepatitis C virus; D013185:Squalene